284 related articles for article (PubMed ID: 32755987)
41. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M.
Maschan A; Myakova N; Aleinikova O; Abugova Y; Ponomareva N; Belogurova M; Fechina L; Fedorova A; Grigor'eva N; Lebedev V; Nikonova O; Shamardina A; Sharapova G; Smirnova N; Rudneva A; Volchkov E; Samochatova E
Br J Haematol; 2019 Aug; 186(3):477-483. PubMed ID: 31069789
[TBL] [Abstract][Full Text] [Related]
42. High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma.
Shi YF; Zhou SJ; Sun L; Yu K; Chen Y
Med Clin (Barc); 2020 Sep; 155(6):235-241. PubMed ID: 32173075
[TBL] [Abstract][Full Text] [Related]
43. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
44. Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
Engelhard M
Clin Immunol; 2016 Nov; 172():101-104. PubMed ID: 27531574
[TBL] [Abstract][Full Text] [Related]
45. Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.
Sheikh IN; Elgehiny A; Ragoonanan D; Mahadeo KM; Nieto Y; Khazal S
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740580
[TBL] [Abstract][Full Text] [Related]
46. Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.
Chiappella A; Santambrogio E; Castellino A; Nicolosi M; Vitolo U
Expert Rev Hematol; 2017 Aug; 10(8):697-705. PubMed ID: 28665232
[TBL] [Abstract][Full Text] [Related]
47. Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy.
Maggen C; Dierickx D; Cardonick E; Mhallem Gziri M; Cabrera-Garcia A; Shmakov RG; Avivi I; Masturzo B; Duvekot JJ; Ottevanger PB; O'Laughlin A; Polushkina E; Van Calsteren K; Woei-A-Jin FJSH; Amant F;
Br J Haematol; 2021 Apr; 193(1):52-62. PubMed ID: 32945547
[TBL] [Abstract][Full Text] [Related]
48. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Nowakowski GS; Czuczman MS
Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
[TBL] [Abstract][Full Text] [Related]
49. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
51. Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
Roschewski M; Dunleavy K; Wilson WH
Leuk Lymphoma; 2014 Nov; 55(11):2428-37. PubMed ID: 24438195
[TBL] [Abstract][Full Text] [Related]
52. Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Landsburg DJ; Koike A; Nasta SD; Svoboda J; Schuster SJ; Wasik MA; Caponetti GC
Cancer Immunol Immunother; 2021 Mar; 70(3):869-874. PubMed ID: 32857184
[TBL] [Abstract][Full Text] [Related]
53. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
54. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
55. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
Lu Q; Huang H; Tang S; Wang Y; Yang DH
Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
[TBL] [Abstract][Full Text] [Related]
56. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
[TBL] [Abstract][Full Text] [Related]
57. New developments in the management of diffuse large B-cell lymphoma.
Habermann TM
Hematology; 2012 Apr; 17 Suppl 1():S93-7. PubMed ID: 22507791
[TBL] [Abstract][Full Text] [Related]
58. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cvetković RS; Perry CM
BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
[TBL] [Abstract][Full Text] [Related]
59. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
Molina A
Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation.
Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD
Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]